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stroll through nearly any American gro-
cery store or pharmacy yields ample proof
of the soybean’s increasing role in the U.S.
diet. Food packaging offers statements about products’
soy content and the purported associated health bene-
fits. Products such as tofu, soy milk, soy-based infant
formula, and meatless “texturized vegetable protein”
burgers are widely
available. Shelves of
dietary supplements
and nutraceuticals are
stocked with isofla-
vones, naturally occur-
ring estrogenic com-
pounds found in soy.
The general impres-
sion is one of certain-
ty that both soy and
soy isoflavones deliver
many health benefits,
including prevention of cardiovascular disease, cancer,
and osteoporosis, as well as treatment of menopausal
symptoms. The science is less absolute, however, and
still evolving. 
Soy provides a complete source of dietary protein,
meaning that, unlike most plant proteins, it contains all
the essential amino acids. According to the American
Soybean Association, 3.14 billion bushels (85.5 million
metric tons) of soybeans were harvested in the United
States in 2004. Approximately half of the harvest was
exported, and most of the remainder was crushed to
produce oil and protein meal for domestic use. An April
2006 report from the USDA Economic Research
Service indicates that only a small amount of whole soy-
beans are used to produce soy foods, and just 2% of soy
protein meal is used for human consumption; the rest is
used for animal feed. 
The Soyfoods As-
sociation of North
America reports that
U.S. sales of soy foods
reached $3.9 billion in
2003, continuing an
11-year trend of 15%
average annual increas-
es. According to the
United Soybean Board’s
2004–2005  Consumer
Attitudes About Nutri-
tion report, 25% of Americans consume soy foods or
beverages at least once per week, and 74% view soy
products as healthy. 
Nevertheless, Americans as a whole still consume
very little soy protein. Based on 2003 data from the
UN Food and Agriculture Organization, per-capita soy
protein consumption is less than 1 gram (g) per day
in most European and North American countries,
although certain subpopulations such as vegetarians,
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Asian immigrants, and infants fed soy-based
formula consume more. The Japanese, on
the other hand, consume an average 8.7 g of
soy protein per day; Koreans, 6.2–9.6 g;
Indonesians, 7.4 g; and the Chinese, 3.4 g.
Traditional soy foods include tofu,
which is produced by puréeing cooked soy-
beans and precipitating the solids, and miso
and tempeh, which are made by fermenting
soybeans with grains. “Second generation”
soy products involve chemical extractions
and other processing, and include soy pro-
tein isolate and soy flour. These products
become primary ingredients in items such
as meatless burgers, dietary protein supple-
ments, and infant formula, and are also
used as nonnutritive additives to improve
the characteristics of processed foods.
Health Effects of Soy
Soybeans and soy foods contain a variety of
bioactive components, including saponins,
protease inhibitors, phytic acid, and
isoflavones. Isoflavones belong to a class of
compounds generally known as phytoestro-
gens, plant compounds that have estrogen-
like structures. 
The dominant isoflavone in soy is genis-
tein, with daidzein and glycitein composing
the remainder. Within soy, isoflavones are
almost entirely bound to sugars, producing
the respective compounds genistin, daidzin,
and glycitin. Soy isoflavones have been
linked with numerous health effects, but
the strength of the relationships and
whether the effects are beneficial are strong-
ly debated.
Soy isoflavones are frequently referred to
as weak estrogens, and depending upon the
specific circumstance, they can act as ago-
nists, partial agonists, or antagonists to
endogenous estrogens (such as estradiol)
and xenoestrogens (including phytoestro-
gens) at estrogen receptors. They are not
especially potent, however, and activity
varies by tissue concentration, cell type, hor-
mone receptor type, and stage of differenti-
ation. In addition to their estrogen receptor
activity, isoflavones may also interfere with
steroid metabolism by inhibiting aromatase,
hydroxysteroid dehydrogenase, and steroid
α-reductase, and by altering the ratio of
estradiol metabolites. Soy isoflavones may
also act as antioxidants; inhibitors of pro-
teases, tyrosine kinases, and topoisomerases;
inducers of Phase I and/or Phase II enzymes
such as cytochrome P450s, glutathione S-
transferase, and quinone reductase; and
inhibitors of angiogenesis.
Such activities have potential benefits—
if they occur in the body. Caution is neces-
sary when predicting in vivo potency from
in vitro systems. In vitro systems are valu-
able for investigating the structure–activity
relationships and the mechanisms of
isoflavone actions, but in vitro tests have
used genistein concentrations that may be
five times higher than the peak concentra-
tions seen in human serum, 95% of which
occurs as glucuronide conjugate. Animal
studies also require careful extrapolations
due to how exposure occurs, interspecies
differences in metabolism, and comparabil-
ity of the stage of development at which
exposure occurs.
Retha R. Newbold, a supervisory
research biologist at the NIEHS, is well
aware of these factors. Concerns about
genistein’s effects on reproduction and
development are due in part to her exten-
sive research in mice. Newbold believes
caution is warranted, because her studies,
as well as others, have shown that genistein
has such effects as inducing uterine adeno-
carcinoma in mice and premature puberty
in rats. A recent study led by biologist
Wendy Jefferson in Newbold’s laboratory
and published in the October 2005 issue of
Biology of Reproduction linked genistein
with effects such as abnormal estrous cycle,
altered ovarian function, and infertility in
mice. 
The original interest in soy was fueled by
geographic epidemiology—the observation
that populations that consume a lot of soy,
particularly those in eastern Asia, have less
breast cancer, prostate cancer, and cardiovas-
cular disease, and fewer bone fractures.
Additionally, women in these populations
report fewer menopausal symptoms, such as
hot flashes, and both men and women have
a lower incidence of aging-related brain dis-
eases. Since lifestyle can affect chronic dis-
ease development, and diet is a major
lifestyle factor, traditional Asian diets drew
considerable attention.
Although initial research overestimated
the amount of soy consumed by Asians, the
cumulative evidence of numerous biomark-
er studies has confirmed that their diets are
significantly higher in both isoflavones and
lignans (another phytoestrogen) compared
to the typical Western diet. Studies have
further shown that when Asians emigrate to
Western nations such as the United States
and adopt the prevailing diet, their disease
rates change. 
What’s interesting, says Jay Kaplan,
head of comparative medicine at Wake
Forest University School of Medicine, is
that people who switch to an American-
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G-force. The dominant isoflavone in soy is genistein (above), which within soy is almost always
bound to a sugar molecule, producing genistin (below). Once genistin enters the digestive tract, it
releases its sugar. Most of the “free” genistein is subsequently reconjugated into glucuronides or
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style diet from a traditional diet high in
plant protein take on the disease character-
istics of the host population, not those of
their ancestral population. “It does seem to
be something that’s in the environment,
and it looks like this reliance on plant pro-
teins is one of these things that goes away
after [immigrants have] been here a while,”
Kaplan says. “What also goes away is any
protection from chronic disease that we
ascribe to those populations.” 
By the late 1990s, the epidemiologic
and experimental data seemed strong
enough to support recommendations to
incorporate soy in the diet. Still, not
everyone was convinced.
Isoflavone Variables and Risks
Soy research is complicated because there’s
considerable variation in isoflavone expo-
sure among people classified as soy con-
sumers. Agronomic factors (such as the
soybean cultivar and the environmental
conditions under which the crop grew)
affect a food’s isoflavone profile, as does the
way a soy food is processed. For example,
soy protein concentrate produced by alco-
hol extraction may have only 12.5 mil-
ligrams (mg) total isoflavones per 100 g, in
contrast to the nearly 199.0 mg total
isoflavones per 100 g of full-fat roasted soy
flour. Additionally, the fact that most of
the isoflavones in food occur bound to
sugar affects how they are digested.
Once genistin enters the digestive tract,
it releases its sugar and becomes “free”
genistein. Some of this free genistein is
absorbed. However, most is reconjugated
into glucuronides or sulfates, the primary
circulating forms of genistein, which are
thought to have either low or no biological
activity. Only a very small amount of free
genistein escapes conjugation by the liver
and circulates in that form. 
“People need to know that as it occurs
in soy and other plant products, genistin is
the compound that’s there. The amount of
actual genistein is very low, one percent or
less probably,” says Michael Shelby, director
of the National Toxicology Program’s
Center for the Evaluation of Risks to
Human Reproduction (CERHR). Key
exceptions are fermented products, such as
miso and tempeh, which may contain up to
40% free genistein. 
Several researchers say that figuring out
the pharmacokinetics of genistin and genis-
tein is a vital piece of missing information.
“It’s a matter of finding out how much
genistin is converted to genistein in the
digestive system, and that information is
not known,” says Jefferson. “I don’t think a
lot of this was understood years ago when
some of the animal experiments started,
and at that time we didn’t have a clear
understanding of the metabolism and fate
of these chemicals. We did the best we
could, as a community, to try to use the
compound we thought would be the one
we should look at. I think it’s given us some
excellent starting types of data, where we
know that these compounds are capable of
causing reproductive and developmental
effects.” 
According to Thomas Badger, director
and senior investigator at the Arkansas
Children’s Nutrition Center in Little Rock,
however, these effects are seen only under
certain experimental conditions that are
not likely to occur in humans—and there-
in lies the crux of the debate. Criticisms of
many studies of genistein’s effects on repro-
duction and development have centered on
exposure occurring by injection and conse-
quently bypassing the usual metabolic
pathways. There is also disagreement about
the use of neonatal mice—commonly used
in studies of reproduction and develop-
ment—as a suitable model for predicting
effects in human infants. 
Despite these criticisms, Newbold
stands by her data. “There was some confu-
sion on the fact that in all of our work we
have injected genistein,” she says. “We went
back and did some of the pharmacokinetics
with that to show that the total circulating
amounts of genistein are very similar to
what’s been reported in feeding rats and
also in infants. Metabolism doesn’t have to
be the same, but you have to know that the
active compounds are getting to the target
tissue. Ultimately, a mouse and a rat are not
the human, though. You just have to accept
it and be as careful with your extrapolations
as possible.” 
Further controversy surrounds the fact
that most of the epidemiologic studies of
Asian populations involved whole soy
foods, but animal and human intervention
studies have generally used soy concen-
trates or isolated isoflavones; some animal
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The culture question. Early research looked to the differences in soy consumption between Asian and Western diets to explain differences in disease
rates, but results are far from conclusive.studies used pure genistein. This difference
may have obscured what the health effects
of soy actually are. 
“I’m reasonably sure that any time you
take one of those isoflavones and give it
separately, you don’t see the same effects as
when all three of the isoflavones of soy are
given,” says Kaplan. “Based on everything
that we know, the best health effects prob-
ably come from the whole isolated soy pro-
tein given together. There’s something
about the intact product that seems to be
bioactive that is not able to be replicated
when you begin chopping it up.” 
In  Expert Panel Report on the Repro-
ductive and Developmental Toxicity of
Genistein, a March 2006 review of the lit-
erature on this compound, an expert panel
convened by the CERHR scrutinized what
has been learned about human exposure to
genistein and the associated reproductive
and developmental consequences. The
most highly exposed adult population
was Japanese, with a daily average intake
of 0.43 mg per kilogram body weight,
which was approximately 10-fold less than
the no-effect levels found in rodent studies.
Based on the conclusions presented at a
meeting held on 15–17 March 2006, the
panel found little cause for concern about
human exposure to genistein. However, no
consideration was made for the amount of
genistin found in the diet or how much of
it is hydrolyzed in the digestive system to
genistein. Further, the panel’s conclusions
were not unanimous. 
Considerably less attention has
attached to daidzein, though there are cur-
rently indicators that it may play a larger
role than genistein in soy’s apparent bene-
ficial health effects. Like genistein,
daidzein in soy exists primarily in linkage
with a sugar molecule. This complex,
daidzin, is hydrolyzed and the sugar mole-
cule removed in the gut. Daidzein can also
be conjugated to glucuronic acid or sulfate
in the gut and liver. It may also be con-
verted to equol (suspected of having a
higher estrogenic potency than the original
daidzein) by gastrointestinal bacteria.
There is considerable variability in individ-
uals’ ability to produce equol, and the
metabolic pathways for both genistein and
daidzein may vary due to factors such as a
person’s particular microflora, intestinal
transit time, and current or recent use of
antibiotics and other drugs.
Thomas Clarkson, a professor of com-
parative medicine at the Wake Forest
University School of Medicine, points out
that although soy protein has a very large
beneficial effect on cardiovascular health in
monkeys, the effects are much less clear in
women. Daidzein metabolism may be the
key. 
“Our best clue is that all monkeys are
equol producers, but only about twenty-
five or thirty percent of women are equol
producers,” Clarkson explains. “There’s
some suggestion now that those women
who are equol producers do derive some
cardiovascular benefits. The fact that [the
effects are] so profound in monkeys may
have to do with the fact that they’re all
equol producers, and [those effects] may
only be translatable to the women who are
equol producers.” 
There have been only a few studies
that have looked exclusively at glycitein,
the third soy isoflavone, but those have not
been on health effects. There are indicators
from a couple of recent in vitro studies that
glycitein may be protective of bone. Most
glycitein research has focused on determin-
ing how to detect the compound, and its
estrogenicity and metabolism.
Soy-Based Infant Formula
Approximately 20–25% of U.S. infants
receive at least some soy-based formula in
their first year (there are no numbers on
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Boon or bane? The touted benefits of consuming soy as part of a healthy diet or ingesting soy sup-
plements as a remedy for menopause symptoms are many, but some data suggests cause for concern.Environmental Health Perspectives • VOLUME 114 | NUMBER 6 | June 2006 A 357
how many are exclusively fed soy formula).
Unlike soy milk, which is sometimes mis-
takenly—and tragically—used in its place,
soy formula contains soy protein isolate sup-
plemented with additional amino acids,
minerals, vitamins, and fats necessary to
support infant growth and development.
Parents may choose soy formula for babies
who are allergic to cow’s milk–based formu-
la or if they themselves do not consume
dairy products. 
Steroid hormones affect myriad process-
es during development, including the for-
mation of hormone-responsive tissues and
organizing and activating effects in the cen-
tral nervous system. Some researchers are
therefore concerned that isoflavones from
soy-based infant formula might perturb that
system, with long-term consequences. 
In a study led by Kenneth Setchell at the
Children’s Hospital Medical Center in
Cincinnati and published 5 July 1997 in
The Lancet, infants fed soy formula were
found to receive 28–47 mg of soy isofla-
vones per day. Isoflavones were detected in
blood, showing that infants absorbed the
compounds from the intestine. This was not
a given, since the infant gut is significantly
different from the adult gut and continues
to develop through the first year. 
Biological effects are plausible but not
necessarily detrimental. For example, in a
study comparing the short-term, long-
term, and multigenerational effects of soy
protein isolate, casein, and whey on the
health and development of rats, a group led
by Badger found that soy protein isolate
was protective against chemically induced
breast cancer. This study appeared in the 1
May 2001 issue of the International Journal
of Toxicology.
In advising caution in feeding infants
soy formula, several groups cite a study led
by Richard Sharpe at the Centre for Repro-
ductive Biology in Edinburgh, Scotland.
The study, published in Human Repro-
duction in July 2002, compared infant mar-
mosets fed cow’s milk–based formula with
others that were fed soy-based formula. The
soy-fed marmosets had comparatively lower
testosterone levels and higher numbers of
Leydig cells per testis. However, a follow-up
study published in April 2006, also in
Human Reproduction, indicated no obvious
effects on reproduction. 
One of the few human studies was led
by Brian Strom of the University of Penn-
sylvania in Philadelphia, in conjunction
with the University of Iowa, and published
in the 15 August 2001 issue of JAMA. In
this study, adults who had been in a con-
trolled feeding study during infancy com-
pleted a telephone interview about their
health, development, and reproductive his-
tory. The only significant differences
reported were that women who received soy
formula as infants had slightly longer men-
strual bleeding and more discomfort than
women who had received cow’s milk–based
formula. A follow-up letter to the JAMA
editor pointed out that both the Strom
study and a retrospective epidemiological
study published in the April 1990 issue of
the  Journal of the American College of
Nutrition suggested that consumption of
soy formula could adversely affect immune
function in children.
More human data are clearly needed, as
described in the recent CERHR Expert
Panel Report on the Reproductive and Devel-
opmental Toxicity of Soy Formula. “The find-
ings for soy formula were that there’s just
not enough information to make the call.
I’m not surprised by that at all,” says
Newbold. “Hopefully, the next step that will
come from this is that there certainly will be
more research with soy formula and more
epidemiology studies. That’s definitely what
we’re missing.” 
For their part, both Jefferson and
Newbold caution against using their results
to determine the safety of soy formula,
although they believe their findings of
adverse effects in rodents provide strong
evidence that concern is warranted. Their
findings are not definitive proof that soy
formula is harmful, however. “The studies
in our laboratory are to determine if these
compounds can cause an effect at any dose
level,” says Jefferson. “The studies we do in
our laboratory were designed to study
mechanism, and not specifically intended
for risk assessment.” 
Given the limited evidence for the
health effects of soy isoflavones in infants,
pediatric and health organizations in several
countries suggest caution in feeding soy to
infants and young children. If an infant is
not receiving breast milk (either its mother’s
or a donor’s), cow’s milk–based infant for-
mula is the first recommendation. If there
seems to be a problem with that option, par-
ents shouldn’t automatically switch to soy
formula, assuming dairy allergy or lactose
intolerance. Soybeans are a major allergen,
and a significant percentage of children who
are sensitive to dairy are also sensitive to soy.
However, other experts indicate that soy
formula is an adequate source of nutrition
for infants with more than 40 years of
apparently safe use. “It’s always true that
there could be something subtle that we
didn’t look for or didn’t know to look for,
but so far we haven’t seen any major health
problems,” says Susan Baker, a pediatric
gastroenterologist at the Children’s Hospital
of Buffalo and former chair of the American
Academy of Pediatrics Committee on
Nutrition. Marisa Salcines, director of com-
munications for the Atlanta-based Inter-
national Formula Council, which represents
infant formula manufacturers, adds that
there’s no conclusive evidence for alarm in
terms of genistein in soy formula. “There
haven’t been any studies that have shown
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Bottled ‘beans. About one-quarter of U.S. children receive some soy-based formula. Parents some-
times choose soy formula in the belief that it is less allergenic than cow’s milk–based formula, even
though soybeans themselves are a major allergen.any negative effects in adults who consumed
soy-based infant formulas as babies,” she says.
To clarify whether or not concerns are
justified, Badger is leading the world’s
largest longitudinal, prospective study of
children comparing soy-based formula,
cow’s milk–based formula, and breast
milk. During the study, now in its fourth
year, children receive multiple in-depth
checkups, including assessments of bone
development and health, imaging of
reproductive tissues, and assessments of
brain development and function, metabo-
lism, growth, development, and body com-
position. The research team aims to enroll
600 pregnant women, whose children will
be followed from birth through puberty.
Additionally, Walter Rogan, a senior
investigator in the NIEHS Epidemiology
Branch, is heading the Study of Estrogen
Activity and Development. Through pilot
studies conducted in late 2004 at the Chil-
dren’s Hospital of Boston and the
Children’s Hospital of Philadelphia,
researchers gathered physical, sonograph-
ic, and biochemical data from infants fed
soy formula, cow’s milk formula, or breast
milk. Data analysis is currently under way. 
Finessing Investigations
On balance it does not seem that soy and
its constituent isoflavones have met origi-
nal expectations. Clinical results with
regard to soy’s ability to reduce the risk of
cardiovascular disease have been inconsis-
tent; a review in the 21 February 2006 issue
of Circulation indicated there was little to
no effect. The only apparent impact of soy
and soy isoflavones on cardiovascular dis-
ease risks seems to be a slight reduction in
low-density lipoproteins in individuals who
had very high levels of cholesterol. An
August 2005 report from the DHHS
Agency for Healthcare Research and
Quality, Effects of Soy on Health Outcomes,
also concluded that there was little evidence
to support a beneficial role of soy and soy
isoflavones in bone health, cancer, repro-
ductive health, neurocognitive function,
and other health parameters. 
Nevertheless, there remain tantalizing
clues that soy may benefit human health.
For example, in vitro studies with human
breast cancer cells suggest that genistein
may induce detoxification enzymes and
inhibit growth of both estrogen recep-
tor–positive and estrogen receptor–nega-
tive cancers. Additionally, in vitro studies
demonstrate that genistein inhibits
prostate cancer cell growth, and epidemi-
ologic studies continue to find an inverse
relationship between consumption of
isoflavone-rich foods and prostate cancer.
Rodent models and in vitro systems have
suggested beneficial effects on bone densi-
ty; similar results have not been observed
in humans, although clinical trials have
shown a promising effect on biomarkers
of bone turnover.
Although there has been comparative-
ly little research on the effects of soy and
isoflavones on cognition and other brain
activity, Clarkson says this area may also
hold some promise. “Our group has done
some work [in monkeys] showing that
[soy] modifies serotonin metabolism in a
direction that should be useful in the pre-
vention of depression,” he says.
Michael R. Adams, a professor of
pathology at Wake Forest University
School of Medicine, has expanded the
scope of the research beyond isoflavones.
He is currently looking at one of soy’s pro-
tein fractions, 7S, which may have a role
in inhibiting the development of athero-
sclerosis by acting directly on the artery
wall rather than on plasma lipids or low-
density lipoprotein cholesterol receptors. 
What most researchers do agree on is
that we are only just beginning to truly
understand the nature of soy, and that
much more research is needed before it is
possible to make firm health recommen-
dations. “If you look at nutritional
research in general,” Kaplan says, “there
are kinds of proteins that are described as
being ‘bioactive.’ Most people had
assumed that if soy is bioactive, it’s because
of the isoflavones. We’re no longer certain
of that at all.”
Julia R. Barrett
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Baby steps toward better understanding. A prospective longitudinal study now in its fourth year seeks to clarify whether concerns about soy-based
infant formula are justified. The study compares the growth and development of children fed cow’s milk–based formula, soy-based formula, or breast
milk, from birth through puberty.TAKE A SMALL STEP TO GET HEALTHY. Get started at www.smallstep.gov
STARTS DOING SIT-UPS DURING COMMERCIALS
GETS 30 MINUTES A DAY OF PHYSICAL ACTIVITY
NO LONGER DEPENDENT ON VERTICALLY STRIPED SHIRTS